ADELAIDE, Australia, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the 42nd Annual J.P. Morgan Healthcare Conference as follows:
A labeling problem has forced Teva to recall 13 lots of fentanyl buccal tablets. Safety updates on the product insert were omitted, the FDA said.
Dr. Reddy's Laboratories on Monday said it entered into a definitive agreement to acquire Mayne Pharma’s US generic prescription product portfolio for $115 million.
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited (“Mayne Pharma”), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, pursuant to which TXMD granted Mayne Pharma an exclusive license to commercialize TXMD’s products in the United States. In addition, TXMD sold certain assets to Mayne Pharma to enable it to commercialize the products.
After the company licensed out its products to Mayne Pharma for $153 million earlier this week, the company is gearing up to lay off its workforce of 212 people, according to a notice filed in Florida.
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited (“Mayne Pharma”), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States. In addition, TXMD has agreed to sell certain assets to Mayne Pharma to allow Mayne Pharma to commercialize the products.
Mayne Pharma's Generic Fentanyl Citrate Receives Approval in the U.S.
Mayne Pharma Generic Haloette Receives Approval in the U.S.
Enforcement Report - Week of June 29, 2022
9 May 2022, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that its application for a Federal Government Modern Manufacturing Initiative (MMI) Grant has been successful. The maximum grant funding is A$4.8 million and is conditional on Mayne Pharma and the Commonwealth entering into a funding agreement.